New neuroimaging techniques yield new insights on Alzheimer's disease

NewsGuard 100/100 Score

Brain imaging can offer a window into risk for diseases such as Alzheimer's disease (AD). A study conducted at the University of Kansas School of Medicine demonstrated that genetic risk is expressed in the brains of even those who are healthy, but carry some risk for AD. The results of this study are published in the November 2009 issue of the Journal of Alzheimer's Disease.

Investigators used automated neuroimaging analysis techniques to characterize the impact of an AD-risk gene, apolipoprotein E (ApoE4), on gray and white matter in the brains of cognitively healthy elderly from the KU Brain Aging Project.

They found that healthy elderly individuals carrying a risk-allele of the ApoE4 gene had reduced cognitive performance, decreased brain volume in the hippocampus and amygdala (regions important for memory processing), and decreased white matter integrity in limbic regions. These type of brain changes are also found in people with AD. Therefore, brain changes, usually found in AD patients, are also evident in nondemented individuals who have a genetic risk of later developing AD.

Lead investigator, Robyn Honea, DPhil, Research Assistant Professor, University of Kansas School of Medicine, Department of Neurology, Alzheimer's and Memory Group, comments, "It is important to note that findings of imaging phenotypes of risk variants, such as with this gene, have been shown in a number of studies. The unique element of our study is that we used several new neuroimaging analysis techniques. In addition, the individuals in our study have been well-characterized in a clinical setting."

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Discovery of toxic and protective short RNAs associated with Alzheimer's disease and superior memory capacity